FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Emergency Use of Adoptive Immunotherapy With CMV-Specific T Cells After Donor Bone Marrow Transplant of an Infant With Immunodeficiency Syndrome and CMV Infection

Conditions: Infection
Precancerous/Nonmalignant Condition

First Posted Date: 2007-10-22

Last Posted Date: 2010-08-24

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00547235

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Effects of Garlic Supplements on Opioids in Healthy Volunteers

Phase 4

Completed

Conditions: Healthy, No Evidence of Disease

Interventions: Dietary Supplement: garlic powder tablets
Drug: oxycodone

First Posted Date: 2007-07-11

Last Posted Date: 2017-04-07

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 15

Registration Number: NCT00499460

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Phase 2

Completed

Conditions: Accelerated Phase Chronic Myelogenous Leukemia
Adult Acute Lymphoblastic Leukemia in Remission
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Hematopoietic/Lymphoid Cancer
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Childhood Acute Myeloid Leukemia in Remission
Chronic Eosinophilic Leukemia
Chronic Phase Chronic Myelogenous Leukemia
Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma
Contiguous Stage II Grade 3 Follicular Lymphoma

Interventions: Drug: placebo
Drug: beclomethasone dipropionate
Drug: tacrolimus
Drug: methotrexate
Procedure: allogeneic hematopoietic stem cell transplantation

First Posted Date: 2007-06-21

Last Posted Date: 2021-02-03

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 140

Registration Number: NCT00489203

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Yoga Study in Breast Cancer Patients

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Other: Delayed yoga classes
Behavioral: Yoga

First Posted Date: 2007-05-21

Last Posted Date: 2012-11-28

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 63

Registration Number: NCT00476203

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission

Phase 2

Completed

Conditions: Lymphoid Leukemia in Remission
Stage II Chronic Lymphocytic Leukemia
Stage III Small Lymphocytic Lymphoma
Stage III Chronic Lymphocytic Leukemia
Stage IV Small Lymphocytic Lymphoma
Stage IV Chronic Lymphocytic Leukemia
Stage I Chronic Lymphocytic Leukemia

Interventions: Combination Product: Tositumomab and Iodine I 131 Tositumomab

First Posted Date: 2007-05-21

Last Posted Date: 2017-10-12

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 16

Registration Number: NCT00476047

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Effect of Aspirin on Mammogram Density in Healthy Postmenopausal Women With a Moderate or High Level of Breast Density

Not Applicable

Completed

Conditions: Mammographic Breast Density

Interventions: Drug: Aspirin
Drug: Placebo

First Posted Date: 2007-05-07

Last Posted Date: 2010-11-15

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 144

Registration Number: NCT00470561

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Effect of a Low-Calorie Diet and/or Exercise Program on Risk Factors for Developing Breast Cancer in Overweight or Obese Postmenopausal Women

Not Applicable

Completed

Conditions: Breast Cancer
Obesity
Weight Changes

Interventions: Behavioral: Exercise intervention
Behavioral: behavioral dietary intervention

First Posted Date: 2007-05-07

Last Posted Date: 2012-09-10

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 439

Registration Number: NCT00470119

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia

Phase 2

Completed

Conditions: Acute Myeloid Leukemia in Remission
de Novo Myelodysplastic Syndrome
Fanconi Anemia
Previously Treated Myelodysplastic Syndrome

Interventions: Procedure: Allogeneic Bone Marrow Transplantation
Drug: Cyclophosphamide
Drug: Cyclosporine
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Mycophenolate Mofetil
Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Radiation: Total-Body Irradiation

First Posted Date: 2007-03-28

Last Posted Date: 2020-01-29

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 6

Registration Number: NCT00453388

Locations: 🇺🇸
Children's Hospital and Research Center at Oakland, Oakland, California, United States
🇺🇸
Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

and more 2 locations

Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases

Phase 2

Terminated

Conditions: Leukemia
Graft Versus Host Disease
Myelodysplastic Syndromes

First Posted Date: 2007-03-22

Last Posted Date: 2017-05-24

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 1

Registration Number: NCT00450983

Locations: 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma

Phase 2

Completed

Conditions: DS Stage I Plasma Cell Myeloma
DS Stage II Plasma Cell Myeloma
DS Stage III Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions: Drug: Clarithromycin
Drug: Dexamethasone
Drug: Lenalidomide

First Posted Date: 2007-03-09

Last Posted Date: 2019-11-13

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 32

Registration Number: NCT00445692

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Home Terms & Conditions Privacy Policy